Fig. 7
Sorafenib treatment was linked to LATS2 downregulation, which contributed to the activation of protective mitophagy. Overexpression of LATS2 augmented the therapeutic response of HepG2 cells to sorafenib via inhibiting mitophagy in a manner dependent on the AMPK–MFN2 pathway